Ready to invest in the future of biotechnology?
Email: invest@ediens.me
Phone: +38 044 123 4567
Address: Kyiv, Ukraine
How we earn and expand
Ediens operates under the Science-to-Business model, transforming cutting-edge scientific developments into profitable products and solutions
Sales of innovative probiotics
(B2C and B2B segments)
Personalized dietary supplements
Analytics + recommendations
Microbiome diagnostic services
Subscription
Ecological solutions for water and soil purification
Technology licensing and partner programs
SCIENTIFIC BACKGROUND
Experience and base
35+ років
systems research in the field of human microbiota
120 scientific publications
10 international collaborations
Participation in European programs
Horizon 2020, COST Action, GIS-GMC, FP7, 3P Medicine Strategy Guide
7 scientific articles
in Scopus / Springer (2020–2024)
4 patents of Ukraine and the EU
in the field of biotechnology, diagnostics and bioactive compositions
Own database of BAS
20,000+ interactions of substances with microbiota and biomarkers
An algorithm for interpreting microbiome data has been developed
Boyko-Polishchuk Model, 2024
Participation in the creation
Microbiome in 3P Medicine Strategies: The First Exploitation Guide” (Springer, 2023)
WHAT WE CREATE
Ediens develops three interrelated areas:
1. R&D — research platform
Bioinformatic models of the effects of diet and BAS on the microbiota.
AI tools for predicting changes in the microbiome.
Prototypes of personalized nutraceuticals.
Microbiome sequencing and analytics laboratory modules.
2. Products for people (B2C)
Ediens Personal Health Platform is an online service for personalized nutrition, pharmabiotics, and health plans.
Subscription packages (Basic / Pro / Longevity) with microbiota diagnostics, recommendations and expert support.
Mobile application (under development) — integration with wearable devices, health tracking.
3. Biotechnology solutions for partners (B2B)
Platform for clinics, insurance companies, wellness networks.
AI-API for bioinformatics centers and pharmaceutical companies.
Projects with nutraceutical brands — formulas with proven effects on the microbiota.
HOW THE PLATFORM WORKS
Data collection
microbiota analysis (16S, Shotgun) + questionnaire + laboratory indicators
I-processing
Boyko-Polishchuk algorithm analyzes the profile, selects the BAS and diet
Entrance
individual nutrition, biologics and lifestyle plan
Dynamics
periodic renewal of subscription plans
Advantage:
we combine bioinformatics, nutrigenomics and preventive medicine into a single ecosystem
EDIENS ACHIEVEMENTS
Category
Result
Science
150+ publications, 7 international projects, Springer Guide 2023
Innovations
4 patents, own database of BAS, AI model 2024
R&D
20,000+ biosamples in the database, 35 projects with universities
Products
3 active areas (B2C, B2B, FinTech)
Market
3 countries of presence (Ukraine, Poland, Portugal, Bulgaria), EU exit 2025
Partnerships
Clinics, insurers, scientific institutions, biotech incubators
Doctor of Biological Sciences Nadiya Boyko
“Personalization is not about default capsules; it’s about a recommended product for a specific person.”
Doctor of Biological Sciences Nadiya Boyko
"We are open to partnerships and transparent in contracts - this accelerates the implementation of innovations."
Doctor of Biological Sciences Nadiya Boyko
“Growth technologies and validated storage protocols are the foundation of stability and efficiency.”
EDIENS 2025 INVESTMENT ROUND (PRE-SEED)
Phase
Pre-Seed
Target
$400,000
Status
Open (in the process of forming a pool of investors)
Financing model
SAFE / Convertible Note
20% discount, valuation cap — to be determined after the pilot in the EU
Minimum check
$10,000
Investor track
Angels, Longevity Funds, Early-stage Biotech VC
Focus
Development and scaling of the AI core (Ediens Health Intelligence Engine)
European ISO/CE certification
Entering the EU market (B2C + B2Bl)
Marketing and PR in the direction of longevity/AI-health
Benefits for investors
Share in a deep-tech Health Data company
Early access to AI platform and metrics
Priority in the next rounds
Ediens Product Credits (health packages)
PARTNERSHIPS AND PROJECTS
Horizon 2020 / COST Actions
participation in European biomedical programs
Uzhhorod Biotech School
scientific base and laboratory infrastructure
Ediens × National University "UzhNU"
educational track in microbiomics
Insurance companies (Ukraine)
pilots of personalized health packages
People who are changing biotechnology
Nadiya Boyko
Chief Scientific Officer
Taisiya Simochko
Co-founder / CEO
Lesya Yusko
Virology Consultant
Volodymyr Drobnych
Expert in selecting an individual nutrition plan, developer of SOLVER, professor, doctor of physical and mathematical sciences
Volodymyr Polishchuk
IT specialist, developer of hybrid risk assessment models, Doctor of Technical Sciences
Alexander Sokolov
Engineer of the 3rd category
Albert Krastanov
Co-founder of BioMe, co-developer of pharmabiotics “BioMe combi 10+1”, professor, corresponding member of the Bulgarian Academy of Sciences, head of the Department of Biotechnology, University of Food Technologies, Plovdiv
Svitlana Burmey
Customer Service Manager
Anastasia Kolomoyets
Digital Marketing Manager
Anna Koronevych
Business Assistant
Serhiy Sheiko
Full Stack Developer
Vitaly Matveev
Co-founder / Business Director
OUR VISION
The future of medicine is personalization.
Each organism is unique, and the microbiota is the key to its balance.
We create technologies that help people not just live longer, but live better.
Why is Ediens a profitable investment?
A powerful biotechnology market
The global microbiome market is estimated at $56 billion and is growing by 13% annually. We have unique technologies and solutions that meet current trends.
Our publications
Venture financing
For large investors
Co-investment in projects
For private investors
Strategic partnership
For business
Why is Ediens a profitable investment?
Scientific base and partnerships
Ediens collaborates with leading universities, research centers, and medical institutions. Our developments are based on cutting-edge research in the field of microbiome and biotechnology.
Why is Ediens a profitable investment?
Innovative products with high margins
We create next-generation probiotics, personalized nutraceuticals, and environmental solutions that have high commercial appeal.
